The Global Emerging Interventional Cardiac Devices Market Increasing Adoption of New Technologies in Emerging Markets
Provides Impetus to Growth
ND01-54
February 2014
10 ND01-54
Key Findings
• The total revenue generated by sales of emerging interventional cardiac devices globally
in 2013 was estimated to represent a 26.4% increase over the 2012 revenue.
• Revenue in the US market is projected to grow at a compound annual growth rate
(CAGR) of 33.6%, whereas revenue is projected to grow in the European market at
14.4% and in Rest of World (ROW) at 43.1%, indicating the highest growth.
• The emerging interventional cardiac devices market is currently in its growth phase; this
is attributed to increased levels of awareness of various technologies including renal
denervation (RDN), fractional flow reserve (FFR), and left atrial appendage (LAA) and
the availability of various products in the market.
• With the availability of innovative technologies and strong clinical data evidence, the
interventional cardiac devices market is expected to gain momentum in the marketplace.
• The US and European markets are the highest-growing regions in the interventional
cardiology space; however, the growth in these regions is likely to be offset by low
procedural volumes and declining average selling prices (ASPs).
Source: Frost & Sullivan
11 ND01-54
Key Findings (continued)
• With the increase in life expectancy and an aging baby-boomer population as well as the
surge in cardiac morbidities, the need for the emerging interventional cardiology market
is bound to increase dramatically by 2020.
• Of Brazil, Russia, India, China (BRIC), South Africa, and South Korea, India and China
contribute the highest growth in terms of CAGR and are a step ahead of regions such as
South Korea and Russia.
• Nonetheless, the BRIC interventional cardiology device market will increase robustly
over the forecast period. Outside of the BRIC nations, other highly targeted countries
include Australia, Turkey, Indonesia, Malaysia, and Mexico.
Source: Frost & Sullivan
12 ND01-54
Scope and Segmentation
Scope
Geographic Coverage Global: United States, Europe, and ROW
Study Period 2010–2020
Base Year 2013
Forecast Period 2014–2020
Monetary Unit US dollars
Source: Frost & Sullivan
13 ND01-54
Scope and Segmentation (continued)
• This research service analyses key data and information and provides an in-depth analysis of the global
emerging interventional cardiac devices market.
• The study period covered by this service for the emerging interventional cardiac devices market is from
2010 to 2020, with a CAGR period from 2013 to 2020; the base year is 2013, and the forecast period is
from 2014 to 2020.
• The key geographic areas covered in this study include the United States, Europe, and ROW.
• The 5 key segments covered in this study include transcatheter aortic valve replacement (TAVR), renal
denervation (RDN), bronchial thermoplasty (BT), bioresorbable stents, and FFR. This study does not
include other emerging interventional device market segments.
• This study looks at a series of emerging early-stage interventional technologies; as such, it is approved as
is, and there does not need to be an aggregate total market forecast.
• Revenue for emerging interventional cardiac devices manufacturing companies was obtained from
companies’ annual reports and financial statements.
Source: Frost & Sullivan
14 ND01-54
Key Questions This Study Will Answer
Is the interventional cardiac devices market growing, how long will it continue to grow, and at what rate?
What are the key drivers and trends that lead to growth opportunities?
Which are the most promising segments for manufacturing companies to venture into? Who are the key market participants in each segment?
What market predictions for the forecast period will likely affect manufacturers in the interventional cardiac devices market?
Are the products and services offered today meeting customer needs, or is additional development needed?
What are the trends in use and technology, and is there a shift towards any particular product segment?
Source: Frost & Sullivan
15 ND01-54
Compound
Annual Growth
Rate (CAGR)
24.5%
(CAGR, 2013–2020)
Executive Summary—Market Engineering Measurements
Market Stage
Growth
Market Revenue
$1.49 B
(2013)
Market Size for
Last Year of
Study Period
$6.93 B
(2020)
Base Year
Market Growth
Rate
25.2%
Customer Price
Sensitivity
7
(scale:1 [Low] to 10 [High])
Degree of
Technical
Change
7
(scale:1 [Low] to 10 [High])
Total Emerging Interventional Cardiac Devices Market: Global, 2013
For a tabular version click here. Stable Increasing Decreasing
Note: All figures are rounded. The base year is 2013. Source: Frost & Sullivan
Number of
Competitors
More than 15
(active market competitors in base year)
n
Competitor Overview
Market Overview
16 ND01-54
CEO’s Perspective
2 Significant growth of RDN is expected from various other regions, including Canada, Australia, and Latin America.
3 Favourable demographics will continue to drive the adoption of interventional cardiac devices in growing economies.
4 Technology advances will be witnessed especially in areas of bioresorbable stents and LAA.
5
A significant rise in revenue of coronary stents will be witnessed due to the growing adoption of premium-priced drug-eluting stents.
1 Drug-eluting stents may present regulatory and reimbursement challenges across
different regions.
Source: Frost & Sullivan
17 ND01-54
Executive Summary—3 Big Predictions
2 The price of the devices is increasingly becoming a major factor in competitiveness.
3 An increase in minimally invasive procedures is expected to drive the growth of the market in the next few years.
1 With the increasing use of interventional cardiac procedures, the APAC region is under tremendous pressure to increase the number of trained and skilled medical personnel.
Source: Frost & Sullivan